HLS Therapeutics Inc Stock Toronto S.E.
Stocks
AM
CA05328X1015
Pharmaceuticals
OTC Markets Traded| Market Cap | 82.64M 73.43M 68.53M 62.47M 118M 7.94B 119M 829M 321M 4.06B 310M 304M 13.03B | P/E 2026 * |
-13.1x | P/E 2027 * | -38.8x |
|---|---|---|---|---|---|
| Enterprise Value | 82.64M 73.43M 68.53M 62.47M 118M 7.94B 119M 829M 321M 4.06B 310M 304M 13.03B | EV / Sales 2026 * |
1.42x | EV / Sales 2027 * | 1.27x |
| Free-Float |
99.45% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: HLS Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 58 | 01/05/2023 |
John Hanna
DFI | Director of Finance/CFO | 61 | 26/01/2024 |
Jason Gross
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/06/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Rodney Hill
BRD | Director/Board Member | 58 | 12/03/2018 |
John Welborn
CHM | Chairman | 48 | 22/06/2023 |
Norma Beauchamp
BRD | Director/Board Member | 65 | 01/01/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.41% | - | - | 82.64M | |
| -0.61% | -3.43% | +36.07% | +117.61% | 1,019B | |
| -1.02% | -5.60% | +35.72% | +64.82% | 617B | |
| +1.11% | -0.58% | +12.36% | +78.27% | 464B | |
| +0.34% | -3.01% | +61.79% | +41.79% | 356B | |
| -0.95% | -4.05% | +20.54% | +40.33% | 333B | |
| -1.46% | -2.89% | +10.57% | +26.54% | 267B | |
| -1.35% | -5.43% | -6.17% | +8.82% | 244B | |
| -1.04% | -2.79% | +35.30% | +54.42% | 218B | |
| -1.87% | -4.10% | +28.44% | +97.54% | 179B | |
| Average | -0.68% | -3.39% | +26.07% | +58.90% | 410.8B | |
| Weighted average by Cap. | -0.60% | -3.33% | +29.07% | +71.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 58.34M 51.83M 48.38M 44.09M 83.16M 5.61B 83.94M 585M 227M 2.87B 219M 214M 9.2B | 65.06M 57.8M 53.95M 49.17M 92.74M 6.25B 93.61M 653M 253M 3.2B 244M 239M 10.26B |
| Net income | -5.47M -4.86M -4.54M -4.13M -7.8M -526M -7.87M -54.89M -21.27M -269M -20.54M -20.09M -863M | -2.16M -1.92M -1.79M -1.64M -3.09M -208M -3.11M -21.72M -8.42M -106M -8.13M -7.95M -341M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
